Alexey Vinogradov
Directeur/Membre du Conseil chez XENETIC BIOSCIENCES, INC.
Fortune : 72 848 $ au 31/05/2024
Profil
Dr. Alexey A.
Vinogradov is an Independent Non-Executive Director at Xenetic Biosciences, Inc. and a Director-Operations & Business Development at Cantreva LLC.
He is on the Board of Directors at Pharmsynthez PJSC, Xenetic Biosciences, Inc. and Avelas Biosciences, Inc. Dr. Vinogradov was previously employed as a General Manager by Togas Middle East LLC, an Independent Director by Argos Therapeutics, Inc., a Branch Manager by Togas Group LLC, a Managing Partner by Pharmstandard Ventures, and an Investment Manager by Bioprocess Capital Partners Ltd.
He received his doctorate degree from Moscow State University Lomonosov.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
31/03/2024 | 18 679 ( 1,21% ) | 72 848 $ | 31/05/2024 |
Postes actifs de Alexey Vinogradov
Sociétés | Poste | Début |
---|---|---|
XENETIC BIOSCIENCES, INC. | Directeur/Membre du Conseil | 19/07/2019 |
PHARMSYNTHEZ | Directeur/Membre du Conseil | 03/08/2023 |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Directeur/Membre du Conseil | 14/03/2017 |
Cantreva LLC | Directeur des opérations | 01/09/2017 |
Anciens postes connus de Alexey Vinogradov
Sociétés | Poste | Fin |
---|---|---|
Togas Middle East LLC | Corporate Officer/Principal | 01/05/2017 |
Togas Group LLC | Corporate Officer/Principal | 01/11/2016 |
ARGOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 10/06/2016 |
Bioprocess Capital Partners Ltd.
Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | Private Equity Investor | 31/12/2010 |
Pharmstandard Ventures
Pharmstandard Ventures Investment ManagersFinance Pharmstandard Ventures (Pharmstd Ventures) is a venture capital subsidiary of Pharmstandard PJSC headquartered in Moscow, Russia. The firm was founded in 2013 by Dr. Andrey Petrov. | Directeur Général | - |
Formation de Alexey Vinogradov
Moscow State University Lomonosov | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
PHARMSYNTHEZ | Health Technology |
XENETIC BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Argos Therapeutics, Inc.
Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Bioprocess Capital Partners Ltd.
Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | Finance |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |
Pharmstandard Ventures
Pharmstandard Ventures Investment ManagersFinance Pharmstandard Ventures (Pharmstd Ventures) is a venture capital subsidiary of Pharmstandard PJSC headquartered in Moscow, Russia. The firm was founded in 2013 by Dr. Andrey Petrov. | Finance |
Cantreva LLC | |
Togas Middle East LLC | |
Togas Group LLC |